GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a single-center, double blind, randomized, parallel-arms study designed to investigate the effects of a six-month treatment with the SGLT2i dapagliflozin on markers of kidney senescence, inflammation and tubulointerstitial damage compared to placebo. These mechanisms of renal damage will be investigated in proximal tubular epithelial cells (PTECs) isolated from urine from patients with CKD with or without T2DM and in renal biopsy specimens in a subgroup of patients with diabetic kidney disease.
Epistemonikos ID: 8ba01713c5400e964ac74b6cc2b52745df931cdf
First added on: May 15, 2024